International Journal of Vascular Medicine / 2020 / Article / Tab 1

Clinical Study

Is Nonmicronized Diosmin 600 mg as Effective as Micronized Diosmin 900 mg plus Hesperidin 100 mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study

Table 1

Characteristics of patients at baseline (per-protocol population).

CharacteristicsD-group
D/H-group
Total

Age (years), mean (SD)43.2 (11.2)45.6 (10.3)44.4 (10.8)
Female gender, (%)52 (91.2)51 (89.5)103 (90.4)
Ethnicity, (%)
 Asian1 (1.8)01 (0.9)
 Caucasian32 (56.1)27 (47.4)59 (51.8)
 Black9 (15.8)9 (15.8)18 (15.8)
 Brown15 (26.3)21 (36.8)36 (31.6)
Body mass index (kg/m2), mean (SD)25.7 (3.4)26.0 (3.6)25.9 (3.5)
Reference leg, (%)
 Right23 (40.4)33 (57.9)56 (49.1)
 Left34 (59.6)24 (42.1)58 (50.9)
CEAP classification, (%)
 C0a01 (1.8)1 (0.9)
 C121 (36.8)20 (35.1)41 (36.0)
 C225 (43.9)21 (36.8)46 (40.4)
 C311 (19.3)15 (26.3)26 (22.8)
Medical history, (%)
 Ear, nose, and throat7 (12.3)3 (5.3)10 (8.8)
 Cardiopulmonary7 (12.3)10 (17.5)17 (14.9)
 Digestive system10 (17.5)6 (10.5)16 (14.0)
 Nervous system4 (7.0)7 (12.3)11 (9.6)
 Musculoskeletal system3 (5.3)3 (5.3)6 (5.3)
 Skin7 (12.3)6 (10.5)13 (11.4)
 Others3 (5.3)8 (14.0)11 (9.6)
Venous symptoms (VAS) (mm)47.1 (8.2)50.3 (9.5)48.7 (9.0)

VAS: visual analog scale; S: symptomatic. aThe patient rated C0 was symptomatic.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.